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The HIV care cascade in Switzerland: reaching
the UNAIDS/WHO targets for patients
diagnosed with HIV
Philipp Kohlera,b,M, Axel J. Schmidta,c,d,M, Matthias Cavassinie,
Hansjakob Furrerf, Alexandra Calmyg, Manuel Battegayh,
Enos Bernasconii, Bruno Ledergerberb, Pietro Vernazzaa,
the Swiss HIV Cohort Study
Objectives: To describe the HIV care cascade for Switzerland in the year 2012.
Design/methods: Six levels were defined: (i) HIV-infected, (ii) HIV-diagnosed, (iii)
linked to care, (iv) retained in care, (v) on antiretroviral treatment (ART), and (vi) with
suppressed viral load. We used data from the Swiss HIV Cohort Study (SHCS)
complemented by a nationwide survey among SHCS physicians to estimate the number
of HIV-patients not registered in the cohort. We also used Swiss ART sales data to
estimate the number of patients treated outside the SHCS network. Based on the number
of patients retained in care, we inferred the estimates for levels (i) to (iii) from previously
published data.
Results: We estimate that (i) 15 200 HIV-infected individuals lived in Switzerland in
2012 (margins of uncertainty, 13 400–19300). Of those, (ii) 12 300 (81%) were
diagnosed, (iii) 12 200 (80%) linked, and (iv) 11 900 (79%) retained in care. Broadly
based on SHCS network data, (v) 10 800 (71%) patients were receiving ART, and (vi)
10400 (68%) had suppressed (<200 copies/ml) viral loads. The vast majority (95%) of
patients retained in care were followed within the SHCS network, with 76% registered
in the cohort.
Conclusion: Our estimate for HIV-infected individuals in Switzerland is substantially
lower than previously reported, halving previous national HIV prevalence estimates to
0.2%. In Switzerland in 2012, 91% of patients in care were receiving ART, and 96% of
patients on ART had suppressed viral load, meeting recent UNAIDS/WHO targets.
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Introduction
Optimal management of HIV-infected individuals depends
on early diagnosis and effective treatment of patients with
HIV-infection [1–3]. Both, diagnosis and treatment result
in a marked reduction of onward transmission and have
thus an important impact on public health [4–6].
Maintaining patients in medical care is another key
element of high-quality HIV management [1].
In 2011, Gardner et al. published a review article on the
spectrum of engagement in HIV care in the USA [7]. The
authors described seven different levels, ranging from
‘unaware of HIV infection’ to ‘fully engaged in HIV care
with suppressed viral load’. This publication has fuelled the
discussion about HIV management, and a number of
experts and decision bodies in the USA have used this
analysis to promote improvement of medical care,
treatment uptake and maintenance [8,9]. Particularly the
potential impact of test-and-treat strategies on HIV
prevention is being heavily debated in light of these results
[1,10]. Subsequent publications have provided more up-to
date estimations for the USA [9,11]. According to the latest
article, 14% of HIV-positive individuals in the USA are
unaware of their infection and 30% of HIV-infected
individuals were under a fully suppressive HIV-therapy in
2011. Many authors have replaced Gardner’s chosen label
with ‘HIV treatment cascade’. We feel that this replace-
ment unnecessarily shifts the focus to aspects of clinical
performance and thus suggests the broader label ‘HIV care
cascade’.
In 2014, Raymond et al. published a comparative analysis
on the HIV care cascade in Europe and high-income
countries. They showed large disparities across countries
and identified so-called key breakpoints, describing the
principal gaps between different steps of the cascade [12].
Lately, the World Health Organisation (WHO) and
UNAIDS have promoted their ‘90–90–90’ targets (90%
– diagnosed, 90% – on-treatment, 90% – suppressed) for
the year 2020 [13]. Better knowledge of the HIV care
cascade in Switzerland and identification of key break-
points could help to implement targeted interventions.
We aimed at estimating the number of HIV-infected
individuals and HIV prevalence, the proportion of
HIV-diagnosed individuals, and the quality of HIV care:
proportions of patients linked to and retained in care, with
antiretroviral treatment (ART), and suppressed viral load.
Methods
HIV care cascade
We defined six levels within the spectrum of engagement
in HIV-care:
1. HIV-infected,
2. HIV-diagnosed,
3. linked to care (having had at least one HIV monitoring),
4. retained in care (having had a HIV monitoring in the last
6 months),
5. on ART,
6. suppressed viral load (<200 copies/ml).
Data sources
All data refer to the year 2012 if not stated otherwise. We
mainly used data from the Swiss HIV Cohort Study
(SHCS) for the calculation of (iv), (v), and (vi). The
SHCS is a prospective cohort study of HIV-diagnosed
patients in Switzerland aged 16 years or older [14]. Socio-
demographic, clinical, and laboratory data are recorded in
6-monthly intervals. Informed consent is obtained from
all participants. As physicians within the SHCS network
also monitor HIV-positive patients not participating in
the SHCS, we complemented these data by adding
information gathered by a survey within the SHCS
network (see supplementary file). We used ART sales data
for Switzerland to adjust for non-SHCS-network
patients. For the estimation of levels (ii) and (iii), we
back-calculated from (iv) using 2010 data generated by
the European men-who-have-sex-with-men Internet
survey (EMIS) [15,16], a 25-language online survey for
men-who-have-sex-with-men (MSM) in 2010, covering
38 European countries, with an analytic sample of
174 209 MSM, including 13 353 with self-reported
diagnosed HIV infection. Level (i) – adding the unknown
number of undiagnosed individuals – was calculated
using different estimates for MSM/IDU vs. other
transmission groups. For all six levels, we calculated an
upper and lower margin of uncertainty (Fig. 1).
Calculation of different levels of HIV care
The six levels of the HIV care cascade in Switzerland are
listed according to the sequence of calculations.
Level (iv): people with diagnosed HIV retained in
care
We used the SHCS database of 12/2014 to count SHCS
patients with at least one viral load measurement in 2012
(Table 1, Level (vi), Data source: SHCS). SHCS patients
are monitored either in an SHCS centre, an affiliated
hospital or a private practice. Since a minorityof patients in
care by SHCS physicians is not registered in the SHCS, we
complemented our data from with information from the
SHCS network survey (Table 1, Level (vi), Data source:
Survey). Missing answers from physicians in affiliated
hospitals or private practices were imputed based on the
proportions of their patients who were registered in the
cohort. Because of this imputation, the respective numbers
in Table 1 are labelled as ‘partly based on estimates’.
For the calculation of the number of patients in care
outside the SHCS network, we asked survey participants
for how many patients in other private practices they
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served as consultants. In a last step, after adding data from
level (v), we extrapolated with the antiretrovirally treated
proportion of patients cared for by private practices, to
have an estimate for the remaining HIV patients in
Switzerland (Table 1, Level (vi), Data source: Estimate).
The margins of uncertainty for patients monitored
outside the SHCS network (Fig. 1) was defined by the
lowest and highest ART proportion in the three different
network categories, and also by the lowest and highest
ART coverage value.
Level (v): people with diagnosed HIV on
antiretroviral therapy
For all SHCS patients, we determined the measurement
of the viral load closest to June 30, 2012. Patients who
started ART before this date were considered to be under
treatment. For non-SHCS patients, we used the survey
results to calculate the numbers and proportions of
patients receiving ART, as in level (iv). Swiss ART sales
data (IMS Health GmbH, Hergiswil, Switzerland) were
used to estimate the number of patients treated outside the
SHCS network. We compared sales data of the three most
commonly prescribed reverse transcriptase inhibitors
(tenofovir disoproxil fumarate, emtricitabine, and lamivudine)
with prescription data (type of drug, start and stop date)
among patients registered in the SHCS. The number of
sold tablets was corrected for hepatitis-B-treatment, based
on the number of SHCS patients treated with tenofovir,
but not with emtricitabine.
Possibly over-estimating the number of treated patients,
we assumed a certain fraction of the medication not being
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Table 1. HIV care cascade in Switzerland. Level (iv): number of patients retained in HIV care; level (v): number (proportion) of patients on
antiretroviral treatment [ART level (vi): number (proportion) of patients with suppressed (<200copies/ml)] viral load; all by type of caregiver and
inclusion in SHCS.
SHCS network (N¼10832)
Outside network
(N¼1645)
Caregiver
SHCS
centres
Affiliated
hospitals
Affiliated private
practices Other private
practices Unknown
N 5615 1536 3682 498 608
Data source SHCS Survey SHCS Survey SHCS Survey Survey Estimate
Level (iv) Retained in care 5059 556 884 652M 3051 631M 498 608MM
Level (v) ART (%a) 4577 (90) 455 (82) 788 (89) 581 (89)M 2814 (92) 567 (90)M 459 (92) 552c (91)M
Level (vi) Suppressed viral load (%b) 4442 (97) 395 (87) 755 (96) 531 (91)M 2729 (97) 537 (95)M 437 (95) 525 (95)MM
Based on SHCS and survey data, unless indicated otherwise: Mpartly based on estimates, MM fully based on estimates. SHCS, Swiss HIV Cohort Study;
ART, antiretroviral therapy; VL< viral load.
a% of patients on ART among those retained in care (UNAIDS/WHO target: 90%).
b% of patients with suppressed viral load among those on ART (UNAIDS/WHO target: 90%).
c198/552 patients indirectly cared for by physicians participating in our survey.
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64% 
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WHO recommendations (90-90-90) 
Fig. 1. HIV care cascade for Switzerland in 2012.Numbers and proportions (estimated total of infected individuals¼100%). Red
horizontal lines indicate the 2014UNAIDS/WHO targets of 90% of the previous level, translating into 90, 71, and 64% of the total.
Columns are sub-divided by reliability. SHCS, Swiss HIV Cohort Study. Vertical error bars indicate the margins of uncertainty.
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consumed by the patient due to change of the ART
regimen or due to expiration. Assuming that with a
change of the ART regimen, two of three medication
packages are discarded, we calculated the number of lost
packets based on the number of ART changes in the
SHCS for 2012.
Given the number of treated patients in the SHCS and the
corrected coverage, the number of patients treated
outside the SHCS was calculated (Table 1, Level (v),
Data source: Estimate). The margins of uncertainty for
patients monitored outside the SHCS network was
defined as described above.
Level (vi): suppressed viral load
For the determination of the number of treated SHCS
patients with suppressed viral load, we extracted those
patients identified in (v) with an HIV-RNA
<200 copies/ml in the measurement closest to 30 June,
2012 between 1 January and 31 December 2012.
For non-SHCS patients, answers to the respective
questions of the survey were used. Similarly to the
previous calculations, the proportion of non-SHCS
patients with suppressed viral load being treated by
SHCS physicians not responding to the survey was
extrapolated.
For patients treated by non-SHCS physicians in private
practices, we imputed the respective proportion for
patients on ART with suppressed viral load of the non-
SHCS physicians who participated in the survey (Table
1). The margins of uncertainty for viral suppression
outside the SHCS network was defined by the lowest and
highest proportion in the different categories (SHCS
database, survey data for SHCS centres, SHCS-affiliated
hospitals and SHCS-affiliated private practices).
Level (iii): people with diagnosed HIV linked to
care
At any point in time, there will be people with diagnosed
HIV who have been linked to care but for whatever
reason dropped out of regular monitoring of their HIV
infection. The number of people linked to care was
calculated by dividing the estimated number of people
retained in care by the proportion of EMIS participants
who had seen a health professional for monitoring their
HIV infection in the last 6 months (definition for
retention in care) among those who ever did so
(definition for linkage to care). For other transmission
groups than MSM, the same proportion was used.
Level (ii): people with diagnosed HIV
Accordingly, the number of people diagnosed with HIV
was calculated by dividing the estimated number of
people linked to care by the proportion of EMIS
participants who ever had their HIV infection monitored
among those who ever had been HIV diagnosed. All
Western European countries including Switzerland
provide universal access to healthcare including free
access to HIV monitoring and treatment. For that reason,
we assumed 95% and 100% to be a realistic range for
both retention and linkage to HIV care (margins of
uncertainty, see Fig. 1).
Level (i): HIV-infected individuals
For the estimation of the number of HIV-infected but
undiagnosed individuals, we assumed that the distribution
of MSM and injection drug users (IDU) would be the
same in the overall HIV population as in the SHCS
(together 57%). We then based our calculations for MSM
on a recent modelling study, where 13.5% of all HIV-
infected MSM were found to be undiagnosed [17]. We
assumed this would be equally valid for IDU who are also
frequently tested. For other transmission groups we
assumed a respective proportion of 25% to account for
known differences in HIV-testing rates and late
presentation [18]. We used the above-mentioned fraction
of 13.5% as a lower limit, and a fraction of 30% as an upper
limit to determine the margins of uncertainty. The
denominator for the prevalence calculation (Swiss
population) was based on official data of the Swiss
Federal Office of Statistics [19].
Results
Summary of the cascade, rounded numbers
In 2012, we estimate that (i) 15 200 individuals (plausible
range: 13 400–19 300) infected with HIV were living in
Switzerland, corresponding to an overall prevalence of
0.19% (plausible range, 0.17–0.24%). Of those, (ii)
12 300 (81%) had been diagnosed, (iii) 12 200 (80% of the
estimated total) were linked, and (iv) 11 900 (79%) were
retained in care. Broadly based on SHCS network data,
(v) 10 800 (71%) patients were receiving ART. Only
about 550 of those cases (5%) were estimated based on
sales data alone. As for treatment success (vi), 10 400
(68%) had suppressed viral loads. The vast majority (95%)
of Swiss HIV patients estimated to be retained in care was
followed within the SHCS network, with 76% registered
in the SHCS. Figure 1 visualizes the numbers and
proportions in all six levels of the HIV care cascade.
Detailed description of levels (ii) and (iii)
According to EMIS data from Switzerland, based on 453
MSM with diagnosed HIV, 98.8% of MSM diagnosed
with HIV had been linked to care, and of those, 98.0%
had been retained in care. These proportions correspond
well with the respective proportions for the 18 EMIS
countries within the WHO Region of Western Europe:
Out of 12 444 respondents diagnosed with HIV 98.3%
(range 97.2–100%) had been linked to care, and of those,
96.5% (range 96.6–100%) had been retained in care.
2512 AIDS 2015, Vol 29 No 18
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Detailed description of levels (iv), (v), and (vi)
Table 1 gives a detailed overview on the number of
patients in levels (iv) to (vi).
SHCS data
In 2012, 8994 patients were followed within the SHCS,
either in a cohort centre (5059), in an affiliated hospital
(884), or in an affiliated private practice (3051).
SHCS network survey data
The overall response rate to our survey requesting
information on additional patients not participating in the
SHCS was 100% for the SHCS centres, 86% in SHCS-
affiliated hospitals, and 92% for SHCS-affiliated private
practices. All survey participants answered that their
numbers were extracted from their respective data bases.
Through this approach, exact treatment information was
available for additional 1701 non-SHCS patients.
Combined
Thus, a total number of 10 832 patients was estimated to
be (retained) in care by a physician within the SHCS
network. Based on the survey, 498 patients were
identified being cared for in private practices outside
the SHCS network.
The corrected SHCS coverage rate of the number of
ART treatments in Switzerland (based on sales data) was
found to be 75.8% in 2012, equalling a total of 10 793
patients on ART. Based on the SHCS data and the results
of our survey, we identified 10 241 patients being treated
in 2012, resulting in 552 additional patients on ART
being cared by physicians not participating in our survey.
ART sales data
In 2012, 215 309 packages were sold, and 159 621 were
prescribed within the cohort (coverage: 74.1%). Adjust-
ment for 1770 therapy stops/changes resulted in a
coverage of 75.8%, reaching from 74.1% for emtricitabine
to 77.8% for lamivudine.
UNAIDS/WHO clinical targets
The overall proportion of patients retained in care who
were under ART was 91% (patients registered in the
SHCS: 91%; patients not registered, but within SHCS
network: 87%). Accordingly, the overall proportion of
treated patients with suppressed viral load was 96%
(patients registered in the SHCS: 97%; patients not
registered, but within SHCS network: 91%).
Discussion
This is the first effort to describe the HIV care cascade for
Switzerland and to estimate the number of people living
with HIV in Switzerland based on clinical (as opposed to
notification) data. Our estimates for the overall number of
HIV-infected individuals and thus HIV prevalence are
substantially lower than previously published. ART
coverage as well as effectiveness of ART for patients in
Switzerland was high: 91% of patients retained in care
(and 88% of HIV-diagnosed patients) were treated; and of
those 96% had had suppressed viral load, thus (nearly)
reaching the UNAIDS/WHO targets (Fig. 1) [13].
A strength of our study is that a majority of HIV-infected
patients in Switzerland is followed within the SHCS
network, allowing us to report highly reliable data on
treatment and treatment success for most patients.
Because of the high percentage of patients followed
within the SHCS network, and because sales data and
SHCS network data on ART use were nearly identical,
we think that our absolute figures for (iv) to (vi) are solid.
Even when applying a stricter lower limit of detection
than 200 copies/ml, 93% among the 8179 patients
registered in the SHCS and receiving ART had less than
50 copies/ml. (This proportion increased to 98.8% when
applying 1000 copies as a lower limit of detection.)
We did not consider ART-packages used for postexposure
prophylaxis (PEP). Even if every working day in
Switzerland one intervention with PEP had been
prescribed, this would only account for 22 patient
packages years. We considered this number to be
negligible. However, adjusting for ART coverage had
the strongest impact on the estimated numbers in all
levels. We thus included the margins of uncertainty as
described above. Applying the current coverage estimate
of 75.8% led to an estimated number of 552 patients on
ART (or 608 patients with diagnosed HIV) being
monitored by unidentified physicians. We feel that this
number is realistic. We might however slightly under-
estimate discarded medication, which would mean that
the true numbers of individuals in all levels are lower than
reported here (but within our margins of uncertainty).
We might over-estimate the proportions linked to/
retained in care. We are aware that the proportions for the
calculations of levels (ii) and (iii) are based on small
numbers. However, because of almost identical pro-
portions based on more than 12 000 respondents from
Western Europe, the proportions we used do not seem to
be biased by small numbers. Nonetheless, our figures for
levels (ii) and (iii) are based on MSM only, and the
extrapolation of those figures to the general HIV-
diagnosed population, and particularly to migrants, can be
questioned. However we have no reason to assume that
the differential regarding linkage to and retention in care
is large, as the distribution of the transmission groups in
the SHCS vs. new notification data in Switzerland is
quite similar.
We did not estimate the number of individuals in need of
ART, as there is increasing evidence for a benefit from
early treatment, and because in Switzerland many patients
HIV care cascade in Switzerland Kohler et al. 2513
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choose to start ART for being sexually noninfectious,
irrespective of their CD4þ cell count [20,21,22].
Our estimate for HIV-infected individuals, and thus
overall HIV prevalence, is substantially lower than
previously published data: Based on cumulated case
reporting within the Swiss surveillance system (adjusted
for mortality), 22 000 to 29 000 persons have been
estimated to be living with HIV in Switzerland in 2012
[23]. This number is however not adjusted for emigra-
tion, and uses 30% for the undiagnosed fraction. Our
estimates for people living with HIV in Switzerland, even
when using 30% as the undiagnosed fraction of all
transmission groups (including MSM and IDU) in
addition to all other upper margins of uncertainty, are
still lower than 20 000. According to the UNAIDS-
Report, the global HIV prevalence (for adults between 15
and 49 years of age) in the year 2011 was 0.8%, ranging
from 0.1% in East Asia to 4.9% in Sub-Saharan Africa. For
Switzerland, the HIV prevalence was estimated at 0.4%
(0.3–0.5%) [24]. Using the same age-restricted denomi-
nator (without respective adjustment of the numerator),
our estimated HIV-prevalence for Switzerland would be
0.29%, with margins of uncertainty of 0.26 and 0.37%.
The number of HIV-infected individuals who are
unaware of their diagnosis cannot be measured directly.
In most versions of the HIV care cascade, it is based on
back-calculation models, or on using the proportion of
individuals who tested positive but were unaware of their
diagnosis in samples that are assumed to be representative
for the underlying population. On the one hand, this
population represents the most important gap in the HIV
care cascade for Switzerland. The risk of onward
transmission of HIV is high in this group given their
nonsuppressed viral load. A certain proportion of these
individuals present with a low CD4þ cell count at time of
diagnosis, which has been shown to be associated with
higher HIV-related morbidity and premature mortality
[4]. It has also been shown that risky behaviour with
respect to HIV transmission is reduced after patients
become aware of their HIV diagnosis [25]. Thus,
minimizing this gap could be a very effective intervention
to improve both individual and public HIV-associated
health aspects. On the other hand, in most publications
on the topic, the number of undiagnosed HIV-infected
individuals is the level of the HIV care cascade with the
highest degree of uncertainty. Because of this problem,
reported cascade proportions that are based on the
estimated number of HIV-infected individuals must be
interpreted with caution, as they largely depend on the
assumptions included in the respective models. We could
conclude that our proportion of 68% with suppressed
viral load among all HIV-infected individuals is high
compared to data from other Western countries, with
Australia achieving the second highest rate with 62% [12].
However, this difference exists because of different
assumptions regarding the undiagnosed fraction, and has
nothing to do with clinical performance. Therefore, we
think it is crucial to relate measures of clinical
effectiveness only to the previous level, and not to re-
calculate the UNAIDS/WHO 90% targets to overall
90–81–73%. Based on the numbers presented here, these
targets translate to 90–70–64% in Switzerland, as
visualized in Fig. 1.
The high rate of successfully treated patients in Switzer-
land might partly be explained by the fact that the vast
majority of HIV-diagnosed patients are being linked to
and treated within the SHCS network. No difference in
treatment effectiveness has been found between patients
being cared by SHCS centres and those by SHCS
physicians in private practice [26]. If the same is true for
patients cared by physicians outside the SHCS network
remains unclear. Of note, according to our own data the
proportion of patients being treated outside the SHCS
network has been increasing in recent years.
Conclusions and recommendations
Our estimate for HIV-infected individuals in Switzerland
is substantially lower than previously reported, halving
national HIV prevalence to 0.2%. Interventions aiming at
improving the current situation of HIV care in Switzer-
land will most likely have the greatest impact if applied to
individuals unaware of their HIV infection.
Although there is strong evidence that the clinical
UNAIDS/WHO 90% targets are met in Switzerland, we
cannot assume that 90% of the HIV-infected population is
also tested and diagnosed. Despite a high treatment
quality of HIV-diagnosed patients, reaching all three
UNAIDS/WHO 90% targets remains a challenge even
for high-income countries with well-established HIV
treatment networks. We recommend separating the
calculation and discussion of UNAIDS/WHO targets
based on outreach and testing vs. those based on
clinical performance.
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